Adenocarcinoma of the esophagogastric junction.
Adenocarcinoma of the esophagogastric junction (EGJ) has increased rapidly in incidence in the latter half of the twentieth century. The increase in incidence has affected white men between the ages of 40 and 60 disproportionately. Understanding the etiology and improving treatment requires careful classification of EGJ tumors. A recent consensus conference recognized three types of EGJ adenocarcinomas: distal esophageal, cardia, and subcardia gastric. Distal esophageal adenocarcinomas are associated with Barrett's esophagus. Helicobacter pylori infection may play a role in some adenocarcinomas of the subcardia, but the association is unproven. Therapy for all types of EGJ tumors is surgical, but multimodal forms of treatment are commonly used because of the advanced stage at which these tumors often present. Several endoscopic options exist for primary therapy of early-stage tumors and for palliation.
Jenkins
T D
TD
Gastroenterology Division, Hospital of the University of Pennsylvania, Philadelphia, USA.
Friedman
L S
LS
D000230:Adenocarcinoma / Q000453:epidemiology / Q000209:etiology / Q000473:pathology* / Q000628:therapy*; D017677:Age Distribution; D001471:Barrett Esophagus / Q000150:complications; D004938:Esophageal Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000473:pathology* / Q000628:therapy*; D004943:Esophagogastric Junction / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D012307:Risk Factors; D017678:Sex Distribution